Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7325 in Adults With Fragile X Syndrome
NCT03140813Phase 1Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Jan 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of azd7325 in Fragile X syndrome (FXS) (6 arms), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Amyloid Precursor Protein at 12 weeks. Started Jan 2018; status: completed.
02
Drugs
azd7325
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT03140813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03140813.